Adimab inks deals with Lilly, Genentech and HGS

Lebanon, NH-based Adimab has added some noteworthy players to its long list of partners trying out its antibody development technology. The 2010 Fierce 15 company announced today that Eli Lilly, Genentech, and Human Genome Sciences have all inked new collaboration deals. "As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder. "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology." Adimab release

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.